Investor Presentation H1 2023

Sales growth of 30% driven by both operating units 5 Investor presentation First six months of 2023 Novo NordiskⓇ Reported geographic sales split for first half of 2023 Reported therapy area sales and growth for first half of 2023 DKK billion Insulin Obesity care GLP-1 Rare disease I Other diabetes DKK North America Operations International Operations I Growth at CER billion Growth at CER 44% 120 60 30% 50% -7% 157% -18% 40 40 20 20 17% International Operations 19% 60 80 17% 40 18% 40 12% 62% -2% IO NAO -25% IO 66% NAO 207% ΙΟ -17% NAO -18% 44% 44% 0 0 NAO ΙΟ EMEA China ROW Total¹ GLP-1 Insulin Obesity care Rare disease IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations; CER: Constant exchange rates Note: Unless otherwise specified, sales growth rates are at CER 1'Other diabetes' is included in Total

View entire presentation